Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst

Tipranks - Tipranks - Wed Apr 2, 2025

In a report released yesterday, Charles Duncan from Cantor Fitzgerald maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), with a price target of $132.00. The company’s shares closed yesterday at $131.87.

Don't Miss Our End of Quarter Offers:

According to TipRanks, Duncan is a top 100 analyst with an average return of 24.9% and a 50.74% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, ACADIA Pharmaceuticals, and Alkermes.

Currently, the analyst consensus on Intra-Cellular Therapies is a Moderate Buy with an average price target of $130.83.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $131.98 and a one-year low of $64.09. Currently, Intra-Cellular Therapies has an average volume of 3.49M.

Read More on ITCI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).